ArticleAsia Pacific allergy2025

Stapokibart (CM310) in patients with uncontrolled seasonal allergic rhinitis (PHECDA): Rationale and design of a multicentre, randomized, double-blind, placebo-controlled study.

Menglin Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.